| Literature DB >> 29569770 |
A Tulzer1, W Arzt2, R Gitter1, C Prandstetter1, E Grohmann1, R Mair3, G Tulzer1.
Abstract
OBJECTIVE: To assess the immediate effects of fetal pulmonary valvuloplasty on right ventricular (RV) size and function as well as in-utero RV growth and postnatal outcome.Entities:
Keywords: congenital heart disease; fetal cardiac intervention; fetal pulmonary valvuloplasty; pulmonary atresia with intact septum
Mesh:
Year: 2018 PMID: 29569770 PMCID: PMC6100104 DOI: 10.1002/uog.19047
Source DB: PubMed Journal: Ultrasound Obstet Gynecol ISSN: 0960-7692 Impact factor: 7.299
Cardiac measurements, before intervention, of 23 fetuses with pulmonary atresia with intact ventricular septum or critical pulmonary stenosis, that underwent fetal pulmonary valvuloplasty
| Parameter |
| Value (median (range)) |
|---|---|---|
| RV/LV ratio | 19 | 0.57 (0.47 to 0.70) |
| TV/MV ratio | 19 | 0.69 (0.62 to 0.97) |
| RV filling time | 19 | 0.28 (0.19 to 0.42) |
| RV length | 18 | –2.95 (–4.64 to –1.33) |
| TV annular diameter | 18 | –1.77 (–3.52 to 0.39) |
| TR Vmax (m/s) | 19 | 4.83 (3.28 to 5.5) |
| TV‐VTI × HR (cm × bpm) | 18 | 821.5 (287.5 to 1859) |
Data not available in all cases.
Duration of tricuspid valve (TV) inflow indexed to cardiac cycle length.
HR, heart rate; RV, right ventricular; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.
Procedure details, complications and outcome of fetal pulmonary valvuloplasty (FPV) performed on 23 fetuses with pulmonary atresia with intact ventricular septum (PAIVS) or critical pulmonary stenosis (CPS)
| Case | Cardiac anatomy | GA at FPV (weeks) | Year of FPV | FPV attempts ( | GA at subsequent FPV(s) (weeks) | Technical success | Balloon/valve ratio | Pericardial effusion n.t. | Bradycardia n.t. | Prediction score | PV gradient (Vmax) after FPV (m/s) | GA at birth (weeks) | Postnatal procedure(s) | Circulation | Follow‐up (years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PAIVS | 27 + 6 | 2000 | 1 | — | Y | 1.0 | N | Y | 3 | ND | 37 + 6 | PV dilatation, modified BT shunt, BT shunt removal at 9 months | BV | 16.36 |
| 2 | CPS | 24 + 0 | 2003 | 1 | — | N | — | N | N | ND | — | 32 + 0 | Modified BT shunt | UV | NND |
| 3 | PAIVS | 32 + 1 | 2007 | 2 | 31 + 2 | Y | ND | N | N | ND | ND | 37 + 1 | PV dilatation, modified BT shunt, BDG and RVOT enlargement | 1.5 V | 9.28 |
| 4 | CPS | 28 + 5 | 2010 | 1 | — | Y | 1.0 | N | N | 3 | 3.1 | 40 + 3 | PV dilatation, RVOT patch, PV valvotomy and modified BT shunt, coiling BT shunt | BV | 7.16 |
| 5 | CPS | 29 + 3 | 2010 | 1 | — | Y | 1.0 | N | N | 0 | 4.4 | 38 + 3 | PV dilatation | BV | 6.82 |
| 6 | PAIVS | 25 + 0 | 2012 | 1 | — | Y | 1.1 | N | N | 3 | 1.3 | 37 + 1 | Valvotomy and modified BT shunt, coiling BT shunt | BV | 4.78 |
| 7 | PAIVS | 31 + 0 | 2013 | 1 | — | N | — | N | N | 3 | — | ND | Modified BT shunt followed by BDG anastomosis and Fontan procedure | UV | LFU |
| 8 | CPS | 26 + 6 | 2013 | 2 | 25 + 4 | Partial | 1.0 | N | N | 3 | 2.1 | 35 + 1 | Modified BT shunt, PV dilatation, BDG and RPA patch | 1.5 V | 3.56 |
| 9 | PAIVS | 25 + 5 | 2014 | 1 | — | Y | 0.9 | N | N | 3 | 3.5 | 40 + 4 | PV dilatation (4×) | BV | 2.40 |
| 10 | PAIVS | 28 + 5 | 2014 | 1 | — | Y | 1.1 | Y | Y | 2 | 2.1 | 37 + 5 | PV dilatation | BV | 2.75 |
| 11 | CPS | 29 + 3 | 2015 | 1 | — | Y | 0.9 | Y | N | 0 | 2.2 | 39 + 1 | PV dilatation | BV | 1.81 |
| 12 | PAIVS | 27 + 5 | 2015 | 2 | 27 + 0 | Y | 0.8 | N | Y | 3 | 3.3 | 39 + 1 | Radiofrequency perforation PV, modified BT shunt, PV dilatation | Undetermined | 1.61 |
| 13 | PAIVS | 23 + 6 | 2015 | 3 | 23 + 5, 28 + 5 | Partial | 0.6 | N | Y | 3 | 1.2 | 38 + 2 | PV perforation and dilatation, modified BT shunt and RVPAC, BDG and RVPAC | 1.5 V | 1.63 |
| 14 | CPS | 25 + 1 | 2015 | 2 | 26 + 2 | Partial | 0.9 | N | Y | 0 | 3.4 | 38 + 3 | PV dilatation | BV | 1.64 |
| 15 | PAIVS | 30 + 4 | 2016 | 2 | 30 + 1 | Y | 0.7 | Y | Y | 2 | 2.9 | 38 + 1 | PV dilatation (2×) | BV | 1.25 |
| 16 | PAIVS | 28 + 3 | 2016 | 2 | 26 + 4 | Y | 1.1 | Y | Y | 2 | ND | 38 + 4 | PV perforation and dilatation, PDA stent, PV dilatation (2×), spontaneous closure of PDA stent, PV dilatation | BV | 1.13 |
| 17 | PAIVS | 27 + 3 | 2016 | 1 | — | Y | 1.2 | N | N | 2 | 3.7 | 38 + 0 | PV dilatation (2×) | BV | 0.90 |
| 18 | CPS | 30 + 1 | 2016 | 1 | — | Y | 0.8 | N | N | 1 | 1.3 | 33 + 5 | PV dilatation (2×) | BV | 0.93 |
| 19 | PAIVS | 27 + 4 | 2016 | 3 | 22 + 3, 26 + 4 | Partial | 0.8 | N | N | 3 | 4.0 | 39 + 3 | PV perforation and dilatation, PDA stent and PV dilatation | BV | 0.78 |
| 20 | PAIVS | 28 + 4 | 2016 | 2 | 28 + 3 | Y | ND | N | Y | ND | ND | 39 + 1 | Modified BT shunt and RVOT enlargement | Undetermined | 0.22 |
| 21 | PAIVS | 29 + 1 | 2017 | 1 | — | Y | 1.1 | N | N | 1 | 2.8 | 30 + 4 | No intervention | BV | 0.1 NND |
| 22 | CPS | 28 + 3 | 2017 | 1 | — | Y | ND | N | Y | 0 | 1.6 | 35 + 5 | PV dilatation | BV | 0.24 |
| 23 | PAIVS | 29 + 5 | 2017 | 2 | 29 + 0 | Y | 1.0 | N | N | 3 | 3.5 | 30 + 1 | On i.v. prostaglandins at last follow‐up | Undetermined | 0.11 |
Assessed by four‐point scoring system of Roman et al.15 (criteria: tricuspid/mitral valve annular diameter ratio < 0.7, RV/LV length ratio < 0.6, RV filling time < 31.5% of cardiac cycle length, presence of RV sinusoids) indicating non‐BV circulation after birth for fetuses with score of 3 with 100% sensitivity and 75% specificity.
Patient followed up and treated at our institution. 1.5 V, one‐and‐a‐half ventricle circulation; BDG, bidirectional Glenn anastomosis; BT shunt, Blalock–Taussig shunt; BV, biventricular; GA, gestational age; i.v., intravenous; LFU, lost to follow‐up; LV, left ventricle; N, no; ND, no data available; NND, neonatal death; n.t., necessitating treatment; PDA, persistent ductus arteriosus; PV, pulmonary valve; RPA, right pulmonary artery; RV, right ventricle; RVOT, right ventricular outflow tract; RVPAC, right ventricle‐to‐pulmonary artery conduit; TV, tricuspid valve; UV, univentricular; Y, yes.
Figure 1Cardiac measurements before and after completely or partially successful fetal pulmonary valve intervention in 21 fetuses with pulmonary atresia with intact ventricular septum or critical pulmonary stenosis. Patients 6 and 23 were excluded from (c) and (e) due to exclusive retrograde filling of right ventricle by severe pulmonary regurgitation. HR, heart rate; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.
Cardiac measurements before and after completely successful intervention in 17 fetuses that underwent fetal pulmonary valvuloplasty for pulmonary atresia with intact ventricular septum or critical pulmonary stenosis
| Parameter |
| Value (median (range)) |
| |
|---|---|---|---|---|
| Before intervention | After intervention | |||
| RV/LV ratio | 14 | 0.57 (0.47 to 0.70) | 0.64 (0.58 to 0.75) | 0.0001 |
| TV/MV ratio | 13 | 0.69 (0.62 to 0.83) | 0.78 (0.68 to 0.88) | 0.0004 |
| RV filling time | 13 | 0.28 (0.19 to 0.42) | 0.38 (0.33 to 0.54) | 0.000002 |
| RV length | 13 | –2.95 (–4.64 to –1.33) | –2.08 (–3.85 to –1.09) | 0.0005 |
| TV annular diameter | 13 | –1.81 (–3.52 to –1.31) | –1.56 (–2.55 to –0.53) | 0.0012 |
| TR Vmax | 12 | 4.88 (3.28 to 5.50) | 3.90 (2.74 to 5.38) | 0.0008 |
|
TV‐VTI × HR | 11 | 868 (287.5 to 1859) | 1044 (650 to 1687.5) | 0.008 |
Data not available in all cases.
Duration of tricuspid valve (TV) inflow indexed to cardiac cycle length.
HR, heart rate; RV, right ventricular; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.
Figure 2Apical four‐chamber views of Patient 9 before (a) and 2 days after (b) intervention; arrows mark points of measurement for tricuspid and mitral valve annular diameter and right (RV) and left (LV) ventricular length; note increase in RV length and tricuspid valve diameter after intervention. Pulsed‐wave Doppler traces with RV filling times of Patient 15 before (c) and after (d) intervention; note change from short monophasic RV filling of 25% (107/422 ms) of cardiac cycle length before intervention to longer biphasic RV filling of 39% (197/505 ms) of cardiac cycle length after intervention. LA, left atrium; RA, right atrium; TR, tricuspid regurgitation.
Figure 3Continuous‐wave (CW) Doppler traces of tricuspid regurgitation (TR) in Patient 11 before and after intervention; pressure gradient was reduced from 75 mmHg (4.34 m/s) (a) to 49 mmHg (3.50 m/s) (b). (c) CW Doppler tracing of blood flow across pulmonary valve (PV) with remaining antegrade gradient of 49 mmHg and new pulmonary regurgitation (PR) in Patient 9 after intervention (c).
Figure 4Longitudinal development of right to left ventricular length (RV/LV) ratio (a) and tricuspid to mitral valve annular diameter (TV/MV) ratio (b) in five fetuses that underwent fetal pulmonary valvuloplasty. Plotted are measurements before intervention, immediately after intervention and immediately postpartum, with intervention indicated by asterisks. In Patients 11 and 19, two measurements were performed before intervention. Measurement of TV/MV ratio immediately after intervention is missing for Patient 19 (b). , Patient 6; , Patient 11; , Patient 18; , Patient 19; , Patient 21.
Figure 5Circulation outcome in 23 fetuses that underwent fetal pulmonary valvuloplasty according to prediction score by Roman et al.15, a four‐point scoring system indicating non‐biventricular (BV) circulation after birth for fetuses with score of 3, with 100% sensitivity and 75% specificity. Note that 5/10 patients with predicted non‐BV outcome had BV circulation. 1.5 V, one‐and‐a‐half ventricle circulation; UV, univentricular circulation.